The company is using graphene materials to potentially solve selectivity and detection challenges in biosensing.
Chief executive officer Dr Mohammad Choucair said: “One of Archer’s key execution priorities to deliver value to our shareholders is to prosecute patents related to the development of graphene-based biosensor technology.
“Filing an international patent application represents the first step in the commercialisation of the company’s graphene biosensor technology.
“Importantly, Archer independently generated the IP, and maintains 100% ownership of this new [company] asset, that has the potential to positively disrupt the emerging Medtech industry.”
Protecting intellectual property
The patent application was filed under the PCT with the World International Patent Organisation via IP Australia in compliance with the application process deadline for lodgement of February 15, 2020 - maintaining the priority date established from the company’s provisional patent application.
Filing the PCT application will allow Archer to decide which countries to have patent protection in and will allow for international protection - which can last for up to 20 years
Archer maintains 100% ownership of the International Patent Application and related IP.
Archer anticipates the receipt from WIPO of the application in the next few days.
The company intends to commercialise the biosensing technology by seeking to establish commercial partnerships, including IP and patent licencing agreements, with highly resourced organisations in the biotechnology industry.
Commercialisation involves successfully prosecuting patent applications in Australia and around the world and de-risking the underlying materials technology by progressive development.
Global biosensor market
There are very few materials in existence that can be used to perform biosensing rapidly and accurately for human health diagnostics but Archer’s unique graphene-based materials technology could provide a potential solution due to the use of digital manufacturing to print critical ultrasensitive graphene materials components that are integrated into one or a number of sensors.
The $300+ billion revenue global biotechnology industry is growing, and global biosensor market revenue alone is expected to grow to US$27 billion by 2022.